Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Warrants January 2021 to January 2023
View:
Post by steamfitter on Dec 03, 2021 9:05am

Warrants January 2021 to January 2023

TORONTO, ON / ACCESSWIRE /January 8, 2021 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 4,095,157 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the "Warrants").

The Warrants were issued on January 9, 2019 pursuant to a private placement involving the issuance of 4,095,157 units of the Company. The Company proposes to extend the expiry date of the Warrants that remain outstanding from the original expiry date of January 9, 2021 to January 9, 2023.

Comment by steamfitter on Dec 03, 2021 9:09am
TORONTO, ON / ACCESSWIRE / September 30, 2020 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various ...more  
Comment by Pandora on Dec 03, 2021 9:21am
steamfitter, Yeah, they extended the 50 cent warrants and I think, but I could be wrong, they may have extended some 30 cent warrants but for whatever reason, they did not extend the 37.5 cent warrants, which just happened to be the only ones I owned. Such is life.
Comment by steamfitter on Dec 03, 2021 9:30am
can you give me the time of issue. I never heard of them. 37.5 cents.?
Comment by Pandora on Dec 03, 2021 9:59am
November 7, 2016 --- Financing at 30 cents per unit c/w warrants at 37.5 cents TORONTO, ONTARIO--(Marketwired - Nov. 7, 2016) - NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Theralase Technologies Inc. ("Theralase" or the "Corporation") (TSX VENTURE:TLT)(OTC PINK:TLTFF) is pleased to announce that it proposes to offer for sale up ...more  
Comment by consultant99 on Dec 03, 2021 11:30am
According to the latest finial report there are 72.473 million warrants outstanding as follows: 4.6 M @ 0.375 expiring Jan 2022 3.2 M @ 0.300 expiring Jul 2022 7.3 M @ 0.500 expiring Jan 2023 57.5 M @ 0.35 expiring Aug 2024 As expected the share price got to 0.38 before taking a breather which is the two year high. If we get through this level the stock should run and test the next previous highs ...more  
Comment by menoalittle on Dec 03, 2021 12:45pm
>> According to the latest finial report there are 72.473 million warrants  >> outstanding as follows: >> 4.6 M @ 0.375 expiring Jan 2022 What baloney.  Don't know why you're posting such crappy info (maybe you're just ignorant), but just to clear up any confusion that may have resulted from it, the following is clipped straight from the Q3 ...more  
Comment by cashascars on Dec 03, 2021 1:11pm
Thanks menoalittle, Your the man, I own 3 types of those warrants and the dates your showing are the ones that show in my account.  Although I will not exercise them until the last minute as I do not intend to exercise the warrant only to sell the stock. When I exercise it will be to hold the stock, so there is no reason to exercise early unless the company calls them early.  The one ...more  
Comment by Pandora on Dec 03, 2021 2:31pm
Thanks menoalittle -- I have posted that 'expired' info about the 37.5 cent warrants at least 2 maybe 3 times but it appears many don't read my notes. I now kind of wish they had not expired but they did.
Comment by Rumpl3StiltSkin on Dec 03, 2021 2:40pm
So the total float, outstanding shates + warrants is ~ 270Mil.
Comment by Rumpl3StiltSkin on Dec 03, 2021 3:07pm
Plus those next year warrants that are due to come in til Jan 2023 will bring in ~ $4.5Mil, right?? Plenty of money to run the company until we see end of Phase 2 CR results!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250